10-Q: Meso Numismatics Reports Q1 2024 Results: Revenue Up Slightly, Net Loss Widens

Meso Numismatics, now focused on regenerative medicine through its Global Stem Cells Group, reports a slight increase in revenue but a larger net loss for the quarter ended March 31, 2024.

Summary

• Meso Numismatics, Inc. filed its Form 10-Q for the quarter ended March 31, 2024.
• The company's primary focus is now on regenerative medicine through its subsidiary, Global Stem Cells Group.
• Revenue increased by 3.92% to $817,034 for the quarter, compared to $786,198 in the same period of 2023.
• The net loss for the quarter was $1,961,020, compared to a net loss of $1,670,247 for the same period in 2023.
• The company has an accumulated deficit of $63,951,151 and a working capital deficit of $23,688,329 as of March 31, 2024.
• The company's ability to continue as a going concern is dependent on raising capital.
• The company is in default on several promissory notes.
• The company changed its name to Regenerative Medical Technology Group Inc. and is awaiting FINRA approval.
• The company has material weaknesses in its internal controls over financial reporting.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a slight revenue increase offset by a larger net loss, significant accumulated deficit, and going concern risks. The company's reliance on raising capital and material weaknesses in internal controls contribute to a negative sentiment.

Positives

• Revenue increased by 3.92% compared to the same period in 2023, indicating some growth in the business.
• The opening of the Cancun facility in the second half of 2022 increased sales by providing a facility for physicians to come for training and preform patient procedures.
• The company is integrating every aspect of the regenerative medicine industry.

Negatives

• The net loss increased to $1,961,020 for the quarter, indicating worsening profitability.
• The company has a significant accumulated deficit of $63,951,151.
• The company has a substantial working capital deficit of $23,688,329.
• The company is in default on several promissory notes, raising concerns about its ability to meet its debt obligations.
• The company has material weaknesses in its internal controls over financial reporting, indicating potential risks in financial reporting accuracy.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising capital, which is not guaranteed.
• The company is in default on several promissory notes, and lenders may demand payment or seize assets.
• Material weaknesses in internal controls could lead to errors in financial reporting.
• High interest payments on outstanding liabilities could further strain the company's finances.
• The regenerative medicine industry is subject to legislative and regulatory changes that could impact the company's operations.
• Failure to obtain adequate financing on a timely basis and on acceptable terms to continue as going concern.
• Uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of others intellectual property.

Future Outlook

The company expects revenues to increase in future quarters as a result of ongoing marketing and brand awareness campaigns, training seminars, lectures, and other efforts to expand its presence in the industry. The company also plans to continue to add manufacturing and commercialization of viable cell therapy and immune support related products.

Management Comments

• The increase in revenue was a result of marketing and sales efforts to increase brand recognition and exposure in the industry.
• We experienced more lead generation in 2023 increasing equipment, products, and training sales in regions like Southeast Asia and the Middle East.
• The opening of the Cancun facility in the second half of 2022 also increased sales by providing a facility for physicians to come for training and preform patient procedures.
• We expect that our revenues will increase in future quarters as a result of our ongoing marketing and brand awareness campaigns, training seminars, lectures and other efforts we engage in that expand our presence in the industry and provide us more opportunities to sell our products.
• We expect our overall operating expenses to increase on a quarterly basis for the balance of the year and into 2024 as we further implement our business plan.
• We expect increases in future quarters over all major categories as we engage in efforts to increase brand awareness with our products and services, including advertising campaigns and investor relation services.
• We also expect an increase in general operating costs and growth initiatives as we ramp up operations and seek to expand them.

Industry Context

The company is operating in the regenerative medicine industry, which is experiencing growth as patients seek alternative treatments. The company's strategy of combining clinical research with manufacturing and commercialization aligns with industry trends.

Comparison to Industry Standards

• It is difficult to compare Meso Numismatics directly to industry standards due to its unique combination of historical numismatic business and current focus on regenerative medicine.
• However, companies like Vericel Corporation and Organogenesis Holdings Inc. are comparible in the regenerative medicine space.
• These companies have significantly higher revenue and market capitalization, indicating that Meso Numismatics is still in an early stage of development in this sector.
• Vericel Corporation reported revenue of $46.8 million in Q1 2024, while Organogenesis Holdings Inc. reported revenue of $112.1 million in Q1 2024, both significantly higher than Meso Numismatics' $0.8 million.

Related Party Transactions

• Amounts paid to Enterprise Technology Consulting, a Company 100% owned by Dave Christensen, CEO, for consulting services during the period ended March 31, 2024 and the year ended December 31, 2023 were $22,500 and $90,000, respectively.
• Benito Novas brother, sister and nephew provide marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $65,153 in the aggregate as consultants during the three months ended March 31, 2024, and $101,158 in the aggregate for the three months ended March 31, 2023.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises capital through equity offerings.
• Employees face uncertainty due to the company's going concern risks and potential debt restructuring.
• Creditors face the risk of non-payment due to the company's default on promissory notes.
• Customers may be impacted by the company's ability to provide services and products if it faces financial difficulties.

Next Steps

• The company plans to continue to add manufacturing and commercialization of viable cell therapy and immune support related products.
• The company plans to take remedial action to address material weaknesses in internal controls during the fiscal year ended December 31, 2024.
• The company is currently in debt restructuring talks.

Key Dates

Keywords

regenerative medicine, stem cells, Global Stem Cells Group, numismatics, revenue, net loss, financial results, internal controls, going concern, debt, promissory notes